Printer Friendly

Fluidigm TOPAZ(R) System Instrumental in Solving Asf1 Structure, Advancing Research in Cancer and Genetic Disease.

SOUTH SAN FRANCISCO, Calif. -- The Fluidigm TOPAZ[R] system has played a major role in the structure determination of Anti-Silencing Function 1 (Asf1) with histones H3/H4. Asf1 is a highly conserved chaperone of histones H3/H4 that assembles or disassembles chromatin during transcription, replication, and repair. Understanding the interaction between these proteins can help scientists learn to control and correct the chromosomal defects that can lead to cancer and genetic disease. The research, published in the November 3, 2006 issue of Cell, was conducted at the University of Colorado at Denver and Health Sciences Center. The paper, entitled "Structural Basis for the Histone Chaperone Activity of Asf1," is representative of the ongoing success research groups achieve using the TOPAZ system.

"The TOPAZ system allowed us to identify crystallization conditions we were not able to achieve through years of vapor diffusion trials and allowed us to go from a small amount of sample to having data in about a week," states Mair Churchill, Ph.D., Professor in the Department of Pharmacology at the University of Colorado at Denver and Health Sciences Center. "In addition, the scale-up from TOPAZ crystallization conditions to vapor diffusion was extremely efficient, requiring only 16 conditions to be set."

Researchers used TOPAZ screening chips to identify novel conditions using a small volume construct of the three-protein complex. The most promising conditions were scaled-up using vapor diffusion and standard TOPAZ translation protocols, resulting in 1.7 angstrom resolution of the protein crystal.

The TOPAZ system is unique in its usage of integrated fluidic circuits (IFCs) comprised of a network of channels and valves that enable crystallization study via the free interface diffusion technique. TOPAZ screening chips are capable of running up to 768 experiments in parallel with as little as 10 nanoliters of protein per condition.

About Fluidigm

Fluidigm Corporation develops and distributes systems based on the unique properties of IFCs to precisely control fluids on a nanovolume scale. The company's vision is to create and to lead a new industry in which IFCs bring unparalleled efficiencies to the life science and allied fields. Based in South San Francisco, California, the Company is privately held and backed by premier investors: Versant Ventures, Euclid SR Partners, InterWest Partners, Alloy Ventures, Lehman Brothers Healthcare Fund, the Singapore EDB, Bruce Burrows, Lilly BioVentures, the Invus Group, SightLine Partners, AllianceBernstein and GE Equity.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 7, 2006
Previous Article:Epoch Holding Corporation Announces $10 Million Investment by General American Investors.
Next Article:ATG to Present at the UBS Global Communications and Technology Conference.

Related Articles
Cancer gene gap mapped.
Genetic basis of colon cancer.
The double-edged helix: advances in genetic testing reveal yet another reason we need national health insurance.
The genetic moral code: as we learn about the genetics of sexual orientation, we know that genetics plays a powerful role.
Fellowships, grants, & awards.
Cracking the genomics code: genetic research isn't just for prime-time dramas or high-profile criminal cases. Here's how African American DNA...
The NIH ENDGAME consortium.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters